Table 1 Patient characteristics, median waiting time with interquartile interval from date of diagnosis to treatment and the proportion treated with surgery, radiotherapy or systemic anticancer treatment, among colorectal cancer patients diagnosed in 2015–2016 in Norway
All | Surgery | Radiotherapy | Systemic Anticancer Treatment | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
N (%) | N (%) | p50 [p25, p75] | % treated | N (%) | p50 [p25, p75] | % treated | N (%) | p50 [p25, p75] | % treated | |
Cancer type | ||||||||||
Colon | 5677 (69.1%) | 4672 (76.5%) | 15.0 [3.0, 24.0] | 82.3% | 31 (4.5%) | 34.0 [20.0, 53.0] | 0.5% | 449 (63.9%) | 24.0 [15.0, 37.0] | 7.9% |
Rectal | 2539 (30.9%) | 1433 (23.5%) | 25.0 [14.0, 35.0] | 56.4% | 664 (95.5%) | 33.0 [27.0, 41.0] | 26.2% | 254 (36.1%) | 27.0 [19.0, 38.0] | 10.0% |
Year of diagnosis | ||||||||||
2015 | 4114 (50.1%) | 3074 (50.4%) | 16.0 [4.0, 27.0] | 74.7% | 352 (50.6%) | 34.0 [27.0, 41.0] | 8.6% | 328 (46.7%) | 23.0 [16.0, 36.0] | 8.0% |
2016 | 4102 (49.9%) | 3031 (49.6%) | 17.0 [6.0, 27.0] | 73.9% | 343 (49.4%) | 32.0 [26.0, 40.0] | 8.4% | 375 (53.3%) | 26.0 [18.0, 38.0] | 9.1% |
Age group | ||||||||||
18–49 | 485 (5.9%) | 343 (5.6%) | 11.0 [0.0, 22.0] | 70.7% | 56 (8.1%) | 29.5 [24.5, 38.0] | 11.5% | 60 (8.5%) | 20.5 [17.0, 27.0] | 12.4% |
50–59 | 904 (11.0%) | 609 (10.0%) | 16.0 [2.0, 28.0] | 67.4% | 131 (18.8%) | 33.0 [26.0, 40.0] | 14.5% | 135 (19.2%) | 23.0 [16.0, 32.0] | 14.9% |
60–69 | 2098 (25.5%) | 1535 (25.1%) | 17.0 [4.0, 28.0] | 73.2% | 222 (31.9%) | 33.0 [27.0, 42.0] | 10.6% | 258 (36.7%) | 25.0 [17.0, 38.0] | 12.3% |
70–79 | 2629 (32.0%) | 2095 (34.3%) | 17.0 [8.0, 27.0] | 79.7% | 169 (24.3%) | 34.0 [28.0, 42.0] | 6.4% | 209 (29.7%) | 28.0 [19.0, 41.0] | 7.9% |
80–89 | 1790 (21.8%) | 1361 (22.3%) | 17.0 [7.0, 27.0] | 76.0% | 99 (14.2%) | 33.0 [27.0, 41.0] | 5.5% | 41 (5.8%) | 26.0 [15.0, 47.0] | 2.3% |
90+ | 310 (3.8%) | 162 (2.7%) | 12.0 [0.0, 25.0] | 52.3% | 18 (2.6%) | 30.5 [23.0, 38.0] | 5.8% | 0 (0.0%) | – | 0.0% |
Sex | ||||||||||
Female | 4018 (48.9%) | 3069 (50.3%) | 15.0 [4.0, 26.0] | 76.4% | 282 (40.6%) | 33.5 [26.0, 40.0] | 7.0% | 296 (42.1%) | 24.0 [15.0, 38.5] | 7.4% |
Male | 4198 (51.1%) | 3036 (49.7%) | 18.0 [6.0, 28.0] | 72.3% | 413 (59.4%) | 33.0 [27.0, 41.0] | 9.8% | 407 (57.9%) | 25.0 [18.0, 36.0] | 9.7% |
Stage | ||||||||||
Localised | 1767 (21.5%) | 1670 (27.4%) | 16.0 [0.0, 29.0] | 94.5% | 46 (6.6%) | 32.0 [24.0, 38.0] | 2.6% | 5 (0.7%) | 41.0 [17.0, 62.0] | 0.3% |
Regional | 4118 (50.1%) | 3587 (58.8%) | 17.0 [9.0, 27.0] | 87.1% | 393 (56.5%) | 33.0 [27.0, 40.0] | 9.5% | 74 (10.5%) | 26.0 [17.0, 37.0] | 1.8% |
Metastasis | 1716 (20.9%) | 821 (13.4%) | 13.0 [1.0, 24.0] | 47.8% | 143 (20.6%) | 34.0 [25.0, 45.0] | 8.3% | 463 (65.9%) | 25.0 [16.0, 36.0] | 27.0% |
Unknown | 615 (7.5%) | 27 (0.4%) | 0.0 [0.0, 132.0] | 4.4% | 113 (16.3%) | 34.0 [27.0, 42.0] | 18.4% | 161 (22.9%) | 26.0 [18.0, 38.0] | 26.2% |
Marital status | ||||||||||
Single | 3650 (44.4%) | 2655 (43.5%) | 16.0 [3.0, 27.0] | 72.7% | 298 (42.9%) | 34.0 [26.0, 41.0] | 8.2% | 262 (37.3%) | 26.5 [19.0, 40.0] | 7.2% |
Married | 4566 (55.6%) | 3450 (56.5%) | 17.0 [7.0, 27.0] | 75.6% | 397 (57.1%) | 33.0 [27.0, 40.0] | 8.7% | 441 (62.7%) | 24.0 [16.0, 35.0] | 9.7% |
Income | ||||||||||
Low | 1106 (13.5%) | 816 (13.4%) | 15.0 [3.0, 27.0] | 73.8% | 84 (12.1%) | 31.0 [26.5, 38.5] | 7.6% | 77 (11.0%) | 27.0 [17.0, 39.0] | 7.0% |
Intermediate | 5155 (62.7%) | 3846 (63.0%) | 17.0 [6.0, 27.0] | 74.6% | 422 (60.7%) | 34.0 [27.0, 42.0] | 8.2% | 389 (55.3%) | 26.0 [18.0, 39.0] | 7.5% |
High | 1955 (23.8%) | 1443 (23.6%) | 16.0 [4.0, 28.0] | 73.8% | 189 (27.2%) | 33.0 [25.0, 39.0] | 9.7% | 237 (33.7%) | 24.0 [15.0, 34.0] | 12.1% |
Education | ||||||||||
Low | 2503 (30.5%) | 1830 (30.0%) | 16.0 [5.0, 27.0] | 73.1% | 198 (28.5%) | 33.0 [27.0, 41.0] | 7.9% | 175 (24.9%) | 25.0 [18.0, 38.0] | 7.0% |
Intermediate | 3926 (47.8%) | 2899 (47.5%) | 17.0 [6.0, 27.0] | 73.8% | 370 (53.2%) | 34.0 [27.0, 42.0] | 9.4% | 329 (46.8%) | 25.0 [17.0, 37.0] | 8.4% |
High | 1787 (21.8%) | 1376 (22.5%) | 16.0 [3.0, 27.0] | 77.0% | 127 (18.3%) | 31.0 [22.0, 39.0] | 7.1% | 199 (28.3%) | 25.0 [15.0, 38.0] | 11.1% |
Region | ||||||||||
Southern and Eastern Norway | 4411 (53.7%) | 3349 (54.9%) | 17.0 [5.0, 27.0] | 75.9% | 334 (48.1%) | 37.0 [30.0, 47.0] | 7.6% | 360 (51.2%) | 27.0 [18.0, 39.0] | 8.2% |
Western Norway | 1750 (21.3%) | 1229 (20.1%) | 16.0 [5.0, 28.0] | 70.2% | 155 (22.3%) | 31.0 [26.0, 37.0] | 8.9% | 200 (28.4%) | 21.0 [14.0, 33.5] | 11.4% |
Central Norway | 1220 (14.8%) | 915 (15.0%) | 15.0 [6.0, 25.0] | 75.0% | 116 (16.7%) | 26.5 [19.0, 34.5] | 9.5% | 90 (12.8%) | 23.0 [15.0, 33.0] | 7.4% |
Northern Norway | 835 (10.2%) | 612 (10.0%) | 17.0 [4.0, 30.0] | 73.3% | 90 (12.9%) | 32.5 [27.0, 41.0] | 10.8% | 53 (7.5%) | 30.0 [20.0, 47.0] | 6.3% |
Comorbidity | ||||||||||
No admissions | 309 (3.8%) | 230 (3.8%) | 22.0 [12.0, 33.0] | 74.4% | 31 (4.5%) | 39.0 [31.0, 55.0] | 10.0% | 35 (5.0%) | 30.0 [21.0, 43.0] | 11.3% |
0 | 5926 (72.1%) | 4395 (72.0%) | 16.0 [6.0, 27.0] | 74.2% | 542 (78.0%) | 33.0 [27.0, 40.0] | 9.1% | 555 (78.9%) | 25.0 [17.0, 36.0] | 9.4% |
1–2 | 1671 (20.3%) | 1266 (20.7%) | 15.0 [3.0, 27.0] | 75.8% | 105 (15.1%) | 32.0 [26.0, 43.0] | 6.3% | 108 (15.4%) | 25.0 [16.0, 41.0] | 6.5% |
3+ | 310 (3.8%) | 214 (3.5%) | 17.0 [3.0, 28.0] | 69.0% | 17 (2.4%) | 31.0 [27.0, 40.0] | 5.5% | 5 (0.7%) | 34.0 [33.0, 44.0] | 1.6% |
Emergency Presentation | ||||||||||
No | 5813 (70.8%) | 4455 (73.0%) | 19.0 [11.0, 29.0] | 76.6% | 583 (83.9%) | 34.0 [27.0, 41.0] | 10.0% | 450 (64.0%) | 27.0 [19.0, 39.0] | 7.7% |
Yes | 2403 (29.2%) | 1650 (27.0%) | 7.0 [0.0, 19.0] | 68.7% | 112 (16.1%) | 29.5 [21.0, 38.5] | 4.7% | 253 (36.0%) | 21.0 [14.0, 34.0] | 10.5% |
CPP | ||||||||||
No | 1519 (18.5%) | 1043 (17.1%) | 1.0 [0.0, 18.0] | 68.7% | 40 (5.8%) | 32.5 [24.0, 41.5] | 2.6% | 132 (18.8%) | 21.0 [14.0, 34.0] | 8.7% |
Yes | 6697 (81.5%) | 5062 (82.9%) | 18.0 [10.0, 28.0] | 75.6% | 655 (94.2%) | 33.0 [27.0, 41.0] | 9.8% | 571 (81.2%) | 26.0 [18.0, 38.0] | 8.5% |